



June 1, 2026

BSE Limited

Phiroze Jeejeebhoy
Towers, Dalal Street,
Mumbai 400 001

National Stock Exchange of India Limited

Exchange Plaza, Plot No. C/1, G Block,
Bandra-Kurla Complex, Bandra (East),
Mumbai 400 051

Scrip Code: 523445

Trading Symbol: RIL

Dear Sirs,

Sub.: Newspaper clippings - "Thirty-eighth Annual General Meeting and Information on E-voting" and other related information

This is to inform you that the advertisement on the captioned subject has been published today i.e. June 1, 2026 in the newspapers viz. Financial Express (English) and Navshakti (Marathi).

The newspaper clippings are enclosed for your information and records.

Thanking you,

Yours faithfully,
For **Reliance Industrial Infrastructure Limited**

Amitkumar Mundhe
Company Secretary and Compliance Officer

Encl.: as above

...continued from previous page.

- In case of non-receipt of the LoF, such Public Shareholders of the Target Company may download the same from the SEBI website (www.sebi.gov.in) or obtain a copy of the same from the Registrar to the Open Offer on providing suitable documentary evidence of holding of the Equity Shares of the Target Company and their folio number, DP identity-client identity, current address and contact details.
- The Public Shareholders who tender their Equity Shares in this Open Offer shall ensure that the Equity Shares are clear from all liens, charges and encumbrances. The Offer Shares will be acquired, subject to such Offer Shares being validly tendered in the Open Offer, together with all the rights attached thereto, including all the rights to dividends, bonuses and right offers declared thereof and in accordance with the terms and conditions set forth in the PA, this DPS and as will be set out in the LoF. And the tendering Public Shareholders shall have obtained all necessary consents required by them to tender the Offer Shares on the foregoing basis.
- A Public Shareholder may participate in the Offer by tendering the Equity Shares in the Offer as per the procedure mentioned in the LoF.
- The Open Offer will be implemented by the Acquirer, subject to applicable laws, through the stock exchange mechanism made available by BSE and/or NSE in the form of a separate window ("Acquisition Window") as provided under the SEBI (SAST) Regulations and Master Circular. The detailed procedure for tendering and settlement of shares under the revised mechanism is specified in the Master Circular issued by SEBI bearing reference number SEBI/HO/CFD/PoD-1/P/CIR/2023/31 dated 16 February 2023 ("SEBI Master Circular").
- The Acquirer will appoint a broker for the Open Offer through whom the purchases and settlement of the Offer Shares tendered in the Open Offer shall be made. The details of the buying broker will be provided in the LoF.
- Details of the designated stock exchange for the purpose of tendering the Offer Shares will be updated in the Letter of Offer.
- All Public Shareholders who desire to tender their Equity Shares under the Open Offer will have to intimate their respective depository participants and stock brokers ("Selling Brokers") well in advance to understand the process and methodology in relation to tendering of the Equity Shares through the Stock Exchanges during the Tendering Period.
- The separate Acquisition Window will be provided by BSE and/or NSE to facilitate placing of sell orders. The Selling Broker can enter orders for Equity Shares in dematerialized form.
- The Selling Broker would be required to place an order/bid on behalf of the Public Shareholders who wish to tender Equity Shares in the Open Offer using the Acquisition Window.
- Before placing the order/bid, the Selling Broker will be required to mark a lien on the tendered Equity Shares. Details of such Equity Shares lien marked in the demat account of the Public Shareholders shall be provided by the depository to Indian Clearing Corporation Limited and National Securities Clearing Corporation Limited. The lien marked against unaccepted Equity Shares will be released, if any, to the respective shareholders demat account or would be returned by registered post or by ordinary post or courier (in case of physical shares) at the Public Shareholders' sole risk. Public Shareholders should ensure that their depository account is maintained till all formalities pertaining to the Open Offer are completed.
- In terms of the SEBI Master Circular, Equity Shares tendered in the Open Offer shall be lien marked. Upon finalization of the entitlement, only the accepted quantity of Equity Shares will be debited from the demat account of the concerned Public Shareholder.

- As per the provisions of Regulation 40(1) of the SEBI (LODR) Regulations and SEBI's press release dated 3 December 2018, bearing reference no. PR 49/2018, requests for transfer of securities shall not be processed unless the securities are held in dematerialised form with a depository with effect from 1 April 2019. However, in accordance with the SEBI (SAST) Regulations and the SEBI Master Circular, shareholders holding securities in physical form are allowed to tender shares in an open offer. Such tendering shall be as per the provisions of the SEBI (SAST) Regulations. Accordingly, Public Shareholders holding Equity Shares in physical form as well as eligible to tender their Equity Shares in the Open Offer as per the provisions of the SEBI (SAST) Regulations. Public Shareholders who wish to offer their physical Equity Shares in the Offer are requested to send their original documents as will be mentioned in the letter of offer to the Registrar to the Offer so as to reach them no later than the date of closure of the tendering period for the Open Offer. It is advisable to first email scanned copies of the original documents as will be mentioned in the letter of offer to the Registrar to the Offer and then send physical copies to the address of the Registrar to the Offer as will be provided in the letter of offer. The process for tendering the Offer Shares by the Public Shareholders holding physical Equity Shares will be separately enumerated in the LoF.
 - Public Shareholders may also: (i) download the Letter of Offer from the SEBI website (www.sebi.gov.in); or (ii) obtain a copy of the Letter of Offer by writing to the Registrar to the Open Offer superscripting the envelop "Bliss GVS Pharma Ltd - Open Offer" with suitable documentary evidence of ownership of the Equity Shares of the Target Company and their folio number, depository participant identity - client identity, current address and contact details.
 - Equity Shares shall not be submitted or tendered to the Manager, the Acquirer and/or the Target Company.
 - The cumulative quantity tendered shall be displayed on the websites of the Stock Exchanges throughout the trading session at specific intervals during the Tendering Period.
 - The detailed procedure for tendering the Equity Shares in the Open Offer will be available in the LoF, which is also expected to be available on SEBI's website (www.sebi.gov.in).
- X. OTHER INFORMATION**
- The Acquirer and its directors accept full responsibility for the information contained in the PA and this DPS (other than as specified in paragraph 2 below).
 - The information pertaining to the Target Company contained in the PA or this DPS or any other advertisement/publications made in connection with the Open Offer has been compiled from information published or publicly available sources or provided by the Target Company. The information pertaining to the Sellers contained in the PA or this DPS or any other advertisement/publications made in connection with the Open Offer has been obtained from the Sellers. The Acquirer and the Manager do not accept any responsibility with respect to such information relating to the Target Company and the Sellers contained in the PA or this DPS or any other advertisement/publications made in connection with the Open Offer. The accuracy of such information has not been independently verified by the Acquirer and/or the Manager to the Offer.
 - The Acquirer and its directors accept full responsibility for their obligations under the Open Offer and shall be jointly and severally responsible for the fulfillment of obligation under the SEBI (SAST) Regulations in respect of the Open Offer.
 - Unless otherwise stated, the information set out in this DPS reflects the position as of the date hereof.
 - In this Detailed Public Statement, all references to "₹" are references to Indian Rupee(s).

- In this DPS, any discrepancy in any table between the total and sums of the amount listed is due to rounding off and/or regrouping.
- PA is available and this DPS will be available and accessible on the website of the Manager to the Open Offer at www.sbicaps.com and shall also be available on SEBI's website (www.sebi.gov.in).
- Pursuant to Regulation 12 of the SEBI (SAST) Regulations, the Acquirer has appointed SBI Capital Markets Limited as the Manager to the Open Offer, as per the details below.



Complete Investment Banking Solutions

SBI Capital Markets Limited

Address: 1501, 15th Floor, A & B Wing, Parinee Crescenzo Building, G Block, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051, Maharashtra, India
 Tel: +91 22 4006 9807
 Email: blissgvs.openoffer@sbicaps.com
 Website: www.sbicaps.com
 Contact Person: Kritihika Shetty/Aradhya Rajayaguru
 SEBI registration no.: INM00003531

- The Acquirer has appointed MUFG Intime India Private Limited (Formerly Link Intime India Private Limited) as the Registrar to the Open Offer, as per the details below:



MUFG Intime

MUFG Intime India Private Limited

(Formerly Link Intime India Private Limited)
 Address: C-101, Embassy 247, L B S Marg, Vikhroli (West), Mumbai - 400083, (Maharashtra), India
 Tel: +91 810 811 4949
 Fax: +91 22 49186060
 Email: blissgvspharma.offer@in.mpmf.mufg.com
 Contact Person: Ms. Pradnya Karanjekar
 SEBI registration no.: INR00004058

For and on behalf of the Acquirer

Signed for and on behalf of Anupam Rasayan India Limited (Acquirer)

Sd/-

Authorized Signatory

Place: Surat

Date: 30 May 2026

THE INDIAN WOOD PRODUCTS COMPANY LIMITED

CIN: L20101WB1919PLC0033557

Regd Office: 9, Brabourne Road, Kolkata - 700 001

Email id: iwpho@iwpkatha.co.in, Website: www.iwpkatha.com, Phone: 033 40012813

STATEMENT OF AUDITED STANDALONE & CONSOLIDATED FINANCIAL RESULTS FOR THE YEAR ENDED MARCH 31, 2026

(Rs. in Lakhs)

Particulars	STANDALONE					CONSOLIDATED				
	Quarter Ended		Year Ended			Quarter Ended		Year Ended		
	31.03.2026	31.12.2025	31.03.2025	31.03.2026	31.03.2025	31.03.2026	31.12.2025	31.03.2026	31.03.2025	
Total Income From Operation	6,898.39	5,337.91	5,479.23	22,918.46	22,646.54	6,898.39	5,337.91	5,479.23	22,918.46	22,646.54
Net Profit for the period (before Tax, Exceptional and/or Extraordinary Item)	153.53	166.36	138.22	545.96	506.41	106.35	144.93	156.76	646.83	667.77
Net Profit for the period before tax (after Exceptional and/or Extraordinary items)	153.53	166.36	138.22	545.96	506.41	106.35	144.93	156.76	646.83	667.77
Net Profit for the period after tax (after Exceptional and/or Extraordinary items)#	59.66	121.79	66.11	355.31	367.79	12.48	100.36	84.65	456.18	529.15
Total Comprehensive Income for the period [Comprising Profit for the period(after tax) and Other Comprehensive Income (after tax)]	97.52	117.70	103.41	380.89	352.19	34.74	96.27	106.17	466.16	497.77
Equity Share Capital	1,279.75	1,279.75	1,279.75	1,279.75	1,279.75	1,279.75	1,279.75	1,279.75	1,279.75	1,279.75
Reserves excluding Revaluation reserve:	-	-	-	34,876.83	34,591.90	-	-	-	35,049.78	34,679.57
Earnings per share(Basis & Diluted) (Face value Rs. 2/- per share)	0.09	0.19	0.10	0.56	0.57	0.02	0.16	0.13	0.71	0.83

- The above financial results of the company have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on May 30, 2026. The statutory auditors have carried out an audit of this financial results and has given unmodified opinion on the same.
- The Consolidated results has been prepared in accordance to Equity Method as per Ind AS and includes our share of Profit in the Joint Venture Company i.e. M/s Agro and Spice Trading Pte Ltd, Singapore and its subsidiaries. The results of the Joint Venture Company for the quarter ended December 31, 2025 have been approved by the Company's Board of Directors but have not been subject to Audit or Review.
- For the Financial Year the Board of Directors has recommended a dividend @ 10% (Rs. 0.20 Paise) per share subject to the approval of the shareholders in the ensuing Annual General Meeting.
- On November 21, 2025, the Government of India has implemented four new Labour Codes (the "Labour Codes"), including the Code on Wages, 2019, which amended the definition of "wages". Based on the best information available, the company carried out the estimation of gratuity and long-term compensated absences and recorded a provision of ₹ 13.63 Lakhs primarily arising from the change in "wages" definition. The company continues to monitor the finalization of the Central and State Rules, as well as any further clarifications issued by the Government on other aspects of the Labour Codes and will record appropriate accounting impact as and when such developments occur.
- The figures for the quarter ended March 31, 2026 represents the derived figures between the audited figures in respect of the year ended March 31, 2026 and the unaudited published period to date figures upto December 31, 2025, which was subject to a limited review.
- The previous period figures have been regrouped/rearranged wherever necessary.
- The above is an extract of the detailed format of Quarterly/yearly Result filled with the Stock Exchange under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly/yearly Results are available on the stock exchange's website i.e. www.bseindia.com and also at the website of the Company i.e. www.iwpkatha.com.



By Order of the Board
 Sd/-
 Bharat Mohita
 Chairman and Managing Director
 (DIN : 00392090)

Place : Kolkata
 Date : 30.05.2026



THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND IS NOT A PROSPECTUS ANNOUNCEMENT AND DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES. THIS PUBLIC ANNOUNCEMENT IS NOT INTENDED FOR PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY OUTSIDE INDIA. INITIAL PUBLIC OFFERING OF EQUITY SHARES ON THE EMERGE PLATFORM OF THE NSE LIMITED IN COMPLIANCE WITH THE CHAPTER IX OF THE SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018, AS AMENDED ("SEBI ICDR REGULATIONS").

PUBLIC ANNOUNCEMENT

CELLCRONIC TECHNOLOGIES LIMITED

(Formerly Known as Cellcronic Technologies Private Limited)

CIN: U51900HR2019PLC080744

Our Company was incorporated on June 06, 2019 in the name and style of "Cellcronic Technologies Private Limited" under the provisions of the Companies Act, 2013 vide Certificate of Incorporation bearing CIN: U51900HR2019PTC080744 issued by the Registrar of Companies, Central Registration Centre. Further, our Company was converted into a public limited company pursuant to a resolution passed by our Board of Directors in its meeting held on February 11, 2025 and by the Shareholders in an Extraordinary General Meeting held on February 13, 2025 and consequently the name of our Company was changed to "Cellcronic Technologies Limited" and a fresh Certificate of Incorporation dated March 19, 2025 was issued by the Registrar of Companies, Central Processing Centre. For further details of our company please refer to section titled "History and Corporate Structure" beginning on page no. 160 of this Draft Prospectus.

Registered Office: Shop No. 1, Opp. Newal Power House, Petrol Pump, S.S. Kunipura, Karnal 132023, Haryana, India.
 Contact Person: Mr. Parveen Kumar, Company Secretary and Compliance Officer; E-mail: info@cellcronic.com; Tel: +91 925 497 2951; Website: www.cellcronic.com

PROMOTERS OF OUR COMPANY: RAVINDER MANDHAN, DEEPAK KUMAR AND ANJALI SHEORAN

DETAILS OF THE OFFER

INITIAL PUBLIC OFFER OF UPTO 16,70,000 EQUITY SHARES OF FACE VALUE ₹ 10/- EACH OF OUR COMPANY ("CELLCRONIC" OR THE "COMPANY" OR THE "ISSUER") FOR CASH AT AN OFFER PRICE OF ₹ [a]/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF [a]/- PER EQUITY SHARE ("THE OFFER PRICE"), AGGREGATING TO ₹ [a] LAKHS ("THE OFFER"), COMPRISING OF A FRESH ISSUE OF UPTO 13,50,000 EQUITY SHARES AGGREGATING TO ₹ [a] LAKHS (THE "FRESH ISSUE") AND AN OFFER FOR SALE OF UPTO 3,20,000 EQUITY SHARES BY THE PROMOTER SELLING SHAREHOLDERS ("OFFER FOR SALE") AGGREGATING TO ₹ [a] LAKHS, OUT OF WHICH, [a] EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH FOR CASH AT A PRICE OF ₹ [a]/- PER EQUITY SHARE AGGREGATING TO ₹ [a] LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY MARKET MAKER ("MARKET MAKER RESERVATION PORTION"). THE PUBLIC OFFER LESS THE MARKET MAKER RESERVATION PORTION I.E. OFFER OF [a] EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH AT AN OFFER PRICE OF ₹ [a] PER EQUITY SHARE AGGREGATING U.P. TO ₹ [a] ("NET OFFER"). THE FRESH OFFER AND THE NET OFFER WILL CONSTITUTE [a] % AND [a] % RESPECTIVELY OF THE POST-OFFER PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY. FOR FURTHER DETAILS, PLEASE REFER TO CHAPTER TITLED "TERMS OF THE OFFER" BEGINNING ON PAGE NO. 276 OF THIS DRAFT PROSPECTUS.

THE MINIMUM APPLICATION LOT WILL BE TWO LOTS AND THE OFFER PRICE WILL BE DECIDED BY OUR COMPANY AND THE PROMOTER SELLING SHAREHOLDERS IN CONSULTATION WITH THE LEAD MANAGER AND WILL BE ADVERTISED IN ALL EDITIONS OF [a] (A WIDELY CIRCULATED ENGLISH NATIONAL DAILY NEWSPAPER) AND ALL EDITIONS OF [a] (A WIDELY CIRCULATED HINDI NATIONAL DAILY NEWSPAPER, WHERE OUR REGISTERED OFFICE IS SITUATED), EACH WITH WIDE CIRCULATION, AT LEAST TWO WORKING DAYS PRIOR TO THE OFFER OPENING DATE AND SHALL BE MADE AVAILABLE TO THE EMERGE PLATFORM OF NATIONAL STOCK EXCHANGE OF INDIA LIMITED ("NSE EMERGE") FOR THE PURPOSES OF UPLOADING ON ITS WEBSITE.

The Offer is being made through the Fixed Price Process, in terms of Rule 19(2)(b)(i) of the Securities Contracts (Regulation) Rules, 1957, as amended ("SCRR"), read with Regulation 253(3) of the SEBI ICDR Regulations, as amended, wherein a minimum 50% of the Net Offer is allocated for individual investors who apply for minimum application size and the balance shall be offered to individual applicants who apply for minimum application size and other investors including corporate bodies or institutions, irrespective of the number of specified securities applied for. Provided that the unsubscribed in either category may be allocated to applicants in the other category. For details, see "Offer Procedure" on page no. 289 of this Draft Prospectus.

In terms of the SEBI Circular No. CIR/CFD/POLICYCELL/11/2015, dated November 10, 2015, all potential investors shall participate in the Offer only through an Application Supported by Blocked Amount ("ASBA") process providing details about the bank account, which will be blocked by the Self-Certified Syndicate Banks ("SCSBs") for the same. Further pursuant to SEBI circular bearing no. SEBI/HO/CFD/DIL2/CIR/P/2019/76 dated June 28, 2019, for implementation of Phase II for UPI facility, which is effective from July 01, 2019, all potential applicants to the offer are required to mandatorily utilize the Application Supported by Blocked Amount ("ASBA") process providing details of their respective ASBA accounts or UPI ID (in case of IIS), in which the corresponding Application Amounts will be blocked by the SCSBs or under the UPI Mechanism, as applicable. For details, please refer chapter titled "Offer Procedure" beginning on page no. 289 of this Draft Prospectus. A copy of the Prospectus will be filed with the Registrar of Companies, Haryana at Chandigarh, as required under Section 26 and Section 28 of the Companies Act, 2013.

RISK IN RELATION TO THE FIRST OFFER

This being the first Public Offer of Equity Shares of our Company, there has been no formal market for the Equity Shares. The Face Value of the Equity Shares is ₹ 10/- each. The Offer Price (determined and justified by our Company in consultation with the Lead Manager) as stated under "Basis for Offer Price" beginning on page 97 of this Draft Prospectus should not be taken to be indicative of the market price of the Equity Shares after the Equity Shares are listed. No assurance can be given regarding an active and/or sustained trading in the Equity Shares nor regarding the price at which the Equity Shares will be traded after listing.

LISTING

The Equity Shares offered through the Draft Prospectus are proposed to be listed on the Emerge Platform of the National Stock Exchange of India Limited ("NSE EMERGE") in terms of the Chapter IX of the SEBI (ICDR) Regulations, 2018, as amended from time to time. Our Company has received an "In Principle" Approval Letter dated [a] from the National Stock Exchange of India Limited (NSE EMERGE) for using its name in this Offer Document for listing of our shares on the Emerge Platform of the National Stock Exchange of India Limited. For the purpose of this Offer, the designated Stock Exchange will be the National Stock Exchange of India Limited ("NSE").

GENERAL RISKS

Investments in equity and equity-related securities involve a degree of risk and investors should not invest any funds in this Offer unless they can afford to take the risk of losing their investment. Investors are advised to read the risk factors carefully before taking an investment decision in this Offer. For taking an investment decision, investors must rely on their own examination of our Company and the Offer including the risks involved. The Equity Shares offered in the Offer have neither been recommended nor approved by Securities and Exchange Board of India nor does Securities and Exchange Board of India guarantee the accuracy or adequacy of this Draft Prospectus. Specific attention of the investors is invited to the section titled "Risk Factors" beginning on page no. 23 of this Draft Prospectus.

ISSUER'S AND PROMOTER SELLING SHAREHOLDERS' ABSOLUTE RESPONSIBILITY

Our Company, having made all reasonable inquiries, accepts responsibility for and confirms that this Draft Prospectus contains all information with regard to our Company and the Offer, which is material in the context of the Offer, that the information contained in this Draft Prospectus is true and correct in all material aspects and is not misleading in any material respect, that the opinions and intentions expressed herein are honestly held and that there are no other facts, the omission of which makes this Draft Prospectus as a whole or any of such information or the expression of any such opinions or intentions, misleading in any material respect.

In relation to above, the DP filed with NSE shall be made available to the public for comments, if any, for a period of at least 21 days, from the date mentioned below by hosting it on the respective websites of the Stock Exchange i.e., NSE at www.nseindia.com, website of the Company at www.cellcronic.com and the websites of the Book Running Lead Manager ("BRLM") to the Offer at www.indcap.in.

Our Company hereby invites the members of the public to give comments on the DP filed with NSE with respect to disclosures made in the DP. The members of the public are requested to send a copy of their comments to NSE and/or to the Company Secretary and Compliance Officer (cs@cellcronic.com) of our Company and/or the LM to the Offer at their respective address mentioned herein below in relation to the Offer on or before 5:00 p.m. on the 21 day, i.e. 21 days from the date of filing of "Offer Document" with Emerge Platform Of The National Stock Exchange Of India Limited (NSE EMERGE).

Investments in Equity and Equity-related securities involve a degree of risk and investors should not invest any funds in this Offer unless they can afford to take the risk of losing their entire investment. Investors are advised to read the risk factors carefully before taking an investment decision in the Offer. For taking an investment decision, investors must rely on their own examination of our Company and the Offer including the risks involved. The Equity Shares offered in the issue have not been recommended or approved by the Securities and Exchange Board of India ("SEBI"), nor does SEBI guarantee the accuracy or adequacy of the Draft Prospectus. Specific attention of the investors is invited of the section titled "Risk Factors" beginning on page No. 23 of this Draft Prospectus.

Any decision to invest in the Equity Shares described in the DP may only be made after the Prospectus (Prospectus) has been filed with the RoC and must be made solely on the basis of such Prospectus as there may be material changes in the Prospectus from the Draft Prospectus.

The Equity Shares, when issued, through the Prospectus, are proposed to be listed on the EMERGE Platform of the National Stock Exchange of India Limited (NSE EMERGE). For details of the main objects of our Company as contained in its Memorandum of Association, see "History and Certain Other Corporate Matters" on page 160 of the DP. The liability of the members of our Company is limited. For details of the share capital, capital structure of our Company, the names of the signatories to the Memorandum of Association and the number of shares of our Company subscribed by them of our Company, please see "Capital Structure" beginning on page 71 of the DP.

BOOK RUNNING LEAD MANAGER



Indcap Advisors Private Limited
 Address: Suite# 1201, 12th Floor, Aurora Waterfront, GN 34/1, Sector V, Salt Lake City, Kolkata 700091, West Bengal, India
 Telephone: 033-4069 8001
 Email: smeipo@indcap.in
 Investor grievance email: investors@indcap.in
 Website: www.indcap.in
 Contact Person: Shradha Khanna
 SEBI registration number: INM00013031
 CIN: U74120WB2008PTC125639

REGISTRAR TO THE OFFER



Cameo Corporate Services Limited
 Address: "Sudharmian Building", No. 1, Club House Road, Chennai 600022, Tamil Nadu, India
 Telephone: +91 44-40020700 / 2846 0390
 E-mail: ipo@cameoindia.com
 Investor grievance: investor@cameoindia.com
 Contact Person: Ms K Sreepriya
 Website: www.cameoindia.com
 SEBI Registration Number: INR00003753
 CIN: U67120TN1998PLC041613

All capitalized terms used herein and not specifically defined shall have the same meaning as ascribed to them in the Draft Prospectus.

On behalf of Board of Directors FOR CELLCRONIC TECHNOLOGIES LIMITED

Date: 01.06.2026
 Place: Karnal
 Sd/-
 Mr. Ravinder Mandhan
 Designation: Managing Director

CELLCRONIC TECHNOLOGIES LIMITED is proposing, subject to receipt of requisite approvals, market conditions and other considerations, to make an initial public offer of its Equity Shares and has filed the DP dated May 29, 2026 with NSE on May 29, 2026. The DP shall be available on the website of the NSE at www.nseindia.com and is available on website of the Company i.e. www.cellcronic.com, website of the LM to the Offer, Indcap Advisors Private Limited at www.indcap.in. Potential investors should note that investment in equity shares involves a high degree of risk and for details relating to such risks, please see the section entitled "Risk Factors" on page 23 of the DP and the details as may be set out in the Prospectus, when filed. Potential investors should not rely on the DIP for making any investment decision.

This announcement has been prepared for publication in India and may not be released in the United States. This announcement does not constitute an offer of securities for sale in any jurisdiction, including the United States, and any securities described in this announcement may not be offered or sold in the United States absent registration under the U.S. Securities Act of 1933 or an exemption from registration. Any public offering of securities to be made in the United States will be made by means of a prospectus that may be obtained from the Company and that will contain detailed information about the Company and management, as well as financial information. The securities described in this announcement are not being offered or sold in the United States.

